{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"037-287-696-035-088","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"037-287-696-035-088"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10800,"type":"PATENT","title":"Aarhus University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1140,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8265,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Aarhus Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 786
Search Applicants and Owners separately: \"Aarhus Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 786
i) a nucleotide sequence selected from SEQ ID NO: 7,
ii) a sequence having at least 90% sequence identity with SEQ ID NO: 7, or a fragment consisting of at least 20 consecutive nucleotides thereof, and
iii) a sequence being complementary to this sequence or a fragment consisting of at least 20 consecutive nucleotides thereof."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to any of the preceding claims, wherein the SNP(s) is (are) determined in the transcriptional or translational products of the GPR24 gene as defined in claim 1."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein the transcriptional product of the gene being selected from
(i) nucleic acid sequence identified as SEQ ID NO: 7, or fragments thereof,
(ii) nucleic acid sequences having at least 90% identity with SEQ ID NO: 7 or fragments thereof,
(iii) nucleic acid sequences being complementary to any of the sequences of (i) or (ii),said nucleic acid sequences comprising the polymorphism(s) of the corresponding genomic sequences identified as SEQ ID NO: 7."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein the translational product of the gene being selected from
i) polypeptide sequence identified as SEQ ID NO: 93 , or fragments thereof,
ii) polypeptide sequences having at least 90% identity with the polypeptide sequence of (i), or fragments thereof,said polypeptide sequences comprising a polymorphism(s) corresponding to the polymorphism(s) of the corresponding nucleic acid sequence(s), said nucleic acid sequence(s) being identified as SEQ ID NO: 7 and 93 or SEQ ID NO: 14."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to any preceding claim, wherein the nucleotide sequence is a genomic DNA sequence, a mRNA sequence, or a cDNA sequence."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method according to any preceding claim, wherein amplification comprises use of a primer pair selected from the oligonucleotide sequences identified as SEQ ID NOs: 75-86."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the predisposition to a mental disease is determined by determining the presence of a haplotype comprising the SNPs having refSNP IDs: rs133068, rs133069, rs133070, rs133073 and/or one or more SNPs as defined in claims 3 to 7."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method according to any of the preceding claims, wherein the predisposition to a mental disease is determined by determining in a biological sample isolated from said subject the risky allele(s) of an SNP(s) as defined in claim 3."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A method for determining the absence of predisposition to a mental disease or a protection against a mental disease, such as SCH and/or BPD, in a subject comprising determining in a biological sample isolated from said subject a protective allele of an SNP(s) selected form the SNP(s) as defined in claim 3."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["An isolated oligonucleotide comprising at least 10 contiguous nucleotides being 100% identical to a subsequence of the GPR24 gene comprising or adjacent to a polymorphism or mutation being correlated to an mental disease, said oligonucleotide being selected from the oligonucleotides identified as SEQ ID NO: 75-86."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A diagnostic kit comprising at least two oligonucleotides as defined by the preceding claim 16."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The diagnostic kit according to claim 17, wherein the at least two oligonucleotides are the amplification primers or probes for determining a polymorphism associated with a predisposition to a mental disease, such as SCH and/or BPD, as defined in any of the preceding claims."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The diagnostic kit of claim 18, wherein the primers or probes are selected from the nucleic acid sequences identified as SEQ ID NOs: 75-86."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A gene therapy vector comprising
(i) a DNA sequence selected from the sequences identified as SEQ ID NO 7, or a fragment consisting of at least 20 consecutive nucleotides thereof, or
(ii) a DNA sequence selected from the sequences identified as SEQ ID NO: 14, or a fragment consisting of at least 20 consecutive nucleotides of said DNA sequence."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The gene therapy vector according to claim 20, wherein the DNA sequence or a fragment consisting of at least 20 consecutive nucleotides thereof comprises the protective allele of an SNP selected from the SNPs as defined in any of claims 3 to 7."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A vector comprising a nucleic acid sequence selected from the nucleic acid sequences identified as SEQ ID NOs: 7 or 14, or a fragment consisting of at least 20 consecutive nucleotides thereof, said sequence, or said fragment comprising a polymorphism associated with a predisposition to an mental disease according to any of the claims 1 to 14, said sequence being operably linked to a promoter sequence capable of directing the expression of a variant protein encoded by said sequence."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A compound capable of
i) modulating expression of the GPR24 gene, said compound being selected from an isolated antisense nucleotide sequence or an nucleotide sequence complementary to the regulatory regions of said gene, said nucleotide sequence being capable of forming triple helix structures that modulate transcription of said gene, and/or
ii) modulating activity of a transcriptional product of the GPR24 gene, said transcriptional product being as defined in claim 9, said compound is selected from an isolated sense or antisense sequence or a ribozyme molecule, and/or
iii) modulating activity of a translational product of the GPR24 gene, said translational product being as defined in claim 10, said compound is an antibody molecule against said translational product or binding partner for said translational product."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["Use of a compound according to claim 23 for the manufacture of a medicament for treatment of a mental disease."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The use according to claim 24, wherein the disease is SCH and/or BPD."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition for the treatment of mental disease, such as SCH and/or BPD, comprising a compound according to claim 23."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a candidate compound for therapeutic treatment of a mental disease, such as SCH and/or BPD, said method comprising an in vitro or in vivo model system comprising a gene according to claim 1 or a product of said gene, said product being a transcriptional product of the gene as defined in claim 9 or a translational product of the gene as defined in claim 10."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 27, said method further comprising a cell expressing a GPR24 gene, a transcriptional product of said gene as defined in claim 9 or a translational product of said gene as defined in claim 10."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["A method for prognosis of the likelihood of development of a mental disease , such as SCH and/or BPD, said method comprising determining a polymorphism of a gene selected from the GPR24 gene, said polymorphism being as defined in any of the claims 1-14."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A method of predicting the likelihood of a subject to respond to a therapeutic treatment of a mental disease, such as SCH and/or BPD, said method comprising determining the genotype of said subject in the chromosome area comprising the GPR24 gene."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 30, wherein the determining of genotypes comprises assessing a polymorphism in the DNA sequence of the GPR24 gene, or the corresponding polymorphism in a transcriptional or translational product of said gene, and/or assessing a polymorphism in the DNA sequence of chromosome 22q13, said polymorphism being in linkage disequilibrium with a SNP of the GPR24 gene."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 31, wherein the polymorphism comprises or corresponds to an SNP selected from the SNPs having refSNP IDs: rs133068, rs133069, rs133070, rs133073."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["A method for assessing a therapeutic treatment for a mental disease, such as SCH and/or BPD comprising using GPR24 genotype data."],"number":33,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}